4D Molecular Therapeutics, Inc. (FDMT) key performance indicators and operating metrics (3 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Number of Randomized Patients in 4FRONT-1 | 523.00 | FY2026-Q1 |
| Fewer Injections (Phase 3 Dose Versus Lower Doses) | 58.00 percent | FY2025-Q3 |
| Phase 3 Dose Reduction in Injection Burden (Percent) | 78.00 percent | FY2025-Q3 |
Back to FDMT overview · FDMT earnings · FDMT holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.